Spectrum Management Group Inc. cut its stake in Becton Dickinson and Co (NYSE:BDX) by 8.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,725 shares of the medical instruments supplier’s stock after selling 150 shares during the period. Spectrum Management Group Inc.’s holdings in Becton Dickinson and were worth $431,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently modified their holdings of the company. Tower View Investment Management & Research LLC boosted its position in Becton Dickinson and by 2.5% in the 1st quarter. Tower View Investment Management & Research LLC now owns 8,330 shares of the medical instruments supplier’s stock valued at $2,080,000 after buying an additional 202 shares during the last quarter. RPG Investment Advisory LLC bought a new position in Becton Dickinson and in the 1st quarter valued at $32,000. Baskin Financial Services Inc. boosted its position in Becton Dickinson and by 5.3% in the 1st quarter. Baskin Financial Services Inc. now owns 73,411 shares of the medical instruments supplier’s stock valued at $18,333,000 after buying an additional 3,676 shares during the last quarter. Raymond James Trust N.A. boosted its position in Becton Dickinson and by 2.0% in the 1st quarter. Raymond James Trust N.A. now owns 7,918 shares of the medical instruments supplier’s stock valued at $1,977,000 after buying an additional 155 shares during the last quarter. Finally, Retirement Systems of Alabama boosted its position in Becton Dickinson and by 1.5% in the 1st quarter. Retirement Systems of Alabama now owns 125,287 shares of the medical instruments supplier’s stock valued at $31,288,000 after buying an additional 1,898 shares during the last quarter. 84.87% of the stock is owned by institutional investors and hedge funds.
BDX has been the topic of a number of recent research reports. Citigroup decreased their price objective on Becton Dickinson and from $279.00 to $256.00 and set a “buy” rating on the stock in a research report on Wednesday, January 2nd. Morgan Stanley cut their price target on Becton Dickinson and from $265.00 to $240.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 2nd. Zacks Investment Research raised Becton Dickinson and from a “hold” rating to a “buy” rating and set a $243.00 price target on the stock in a research note on Tuesday, January 8th. Piper Jaffray Companies increased their price target on Becton Dickinson and to $274.00 and gave the company an “overweight” rating in a research note on Tuesday, February 5th. Finally, TheStreet raised Becton Dickinson and from a “c+” rating to an “a” rating in a research note on Tuesday, February 5th. One analyst has rated the stock with a sell rating, five have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $256.25.
BDX stock opened at $240.02 on Wednesday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.62 and a current ratio of 0.97. The firm has a market capitalization of $64.58 billion, a PE ratio of 21.80, a P/E/G ratio of 1.74 and a beta of 1.21. Becton Dickinson and Co has a twelve month low of $208.62 and a twelve month high of $265.87.
Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, February 5th. The medical instruments supplier reported $2.70 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.58 by $0.12. The business had revenue of $4.16 billion for the quarter, compared to the consensus estimate of $4.10 billion. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. The firm’s revenue was up 35.1% compared to the same quarter last year. During the same quarter last year, the business posted $2.48 EPS. On average, analysts expect that Becton Dickinson and Co will post 12.08 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 29th. Investors of record on Friday, March 8th were paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 1.28%. The ex-dividend date was Thursday, March 7th. Becton Dickinson and’s payout ratio is presently 27.97%.
ILLEGAL ACTIVITY WARNING: “Spectrum Management Group Inc. Sells 150 Shares of Becton Dickinson and Co (BDX)” was first reported by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.baseballdailydigest.com/news/2019/04/17/spectrum-management-group-inc-sells-150-shares-of-becton-dickinson-and-co-bdx.html.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.